SearcharxivSearch

arXiv subjects

Keyvan Alavi

Publications and source records attributed to Keyvan Alavi.

2 recordsLinked to original sources

Manganese-Functionalized GelMA Hydrogels for MRI-Guided Immunotheranostics in Precision Oncology

Precision oncology requires multifunctional platforms capable of integrating accurate tumor diagnosis, localized therapeutic delivery, immune modulation, and real-time monitoring of treatment response. Gelatin methacryloyl (GelMA) hydrogels have emerged as versatile biomaterials for biomedical engineering because of their biocompatibility, extracellular matrix-like structure, tunable mechanical properties, photocrosslinkability, and capacity to incorporate therapeutic agents, imaging probes, and functional nanomaterials. In parallel, manganese-based materials have gained increasing attention as promising alternatives to gadolinium-based magnetic resonance imaging contrast agents and as therapeutic components capable of modulating the tumor microenvironment. Manganese ions and manganese-based nanomaterials can enhance T1-weighted MRI contrast, generate reactive oxygen species, relieve tumor hypoxia, deplete glutathione, promote immunogenic cell death, and activate the cyclic GMP-AMP synthase-Stimulator of Interferon Genes pathway. The integration of manganese-based systems with GelMA hydrogels offers a promising strategy for developing localized, stimuli-responsive, and MRI-guided immunotheranostic platforms. This review summarizes the fundamental properties of GelMA hydrogels, the diagnostic and therapeutic roles of manganese-based materials, strategies for constructing manganese-functionalized GelMA systems, and their potential applications in precision oncology. Current challenges, including manganese-associated toxicity, controlled ion release, mechanical optimization, reproducibility, and clinical translation, are also discussed. Finally, future directions are proposed for the rational design of safe, scalable, and personalized manganese-functionalized GelMA platforms for cancer diagnosis and therapy.

q-bio.BM

A Mini Review on Tumor Organoid-on-a-Chip Technologies in Personalized Oncology

Tumor organoid-on-a-chip platforms represent a cutting-edge fusion of patient-derived organoids with microfluidic technologies, offering unprecedented capabilities for personalized cancer research. These systems overcome limitations of conventional models by enabling precise control over the tumor microenvironment, including nutrient gradients, fluid flow, and immune interactions. Tumor organoids recapitulate patient-specific tumor heterogeneity and genetic landscapes, while microfluidic chips provide dynamic perfusion and mechanical stimuli, enhancing physiological relevance. Together, they facilitate advanced applications such as high-throughput drug screening, immunotherapy testing, and metastasis modeling, showing superior predictive power for clinical outcomes. Despite challenges in standardization, scalability, and integration of complex tumor components, ongoing advances in hydrogel engineering, automation, and artificial intelligence are poised to accelerate their clinical translation. This review highlights current technologies, applications, and future directions of tumor organoid-on-a-chip systems, emphasizing their transformative potential in precision oncology.

q-bio.TO